Sanziguben Polysaccharides Attenuate Renal Epithelial-Mesenchymal Transition in Diabetic Nephropathy through Nrf2-Mediated Regulation of TGF-β1/Smad7 Signaling Pathway

IF 2.1 4区 医学 Q3 PHARMACOLOGY & PHARMACY
Jianing Zhang, Fan Wang, Chang Liu, Xiangyi Lu, Weiping Xu, Yang Yu, Shasha Bai, Zhilian Chen
{"title":"Sanziguben Polysaccharides Attenuate Renal Epithelial-Mesenchymal Transition in Diabetic Nephropathy through Nrf2-Mediated Regulation of TGF-β1/Smad7 Signaling Pathway","authors":"Jianing Zhang,&nbsp;Fan Wang,&nbsp;Chang Liu,&nbsp;Xiangyi Lu,&nbsp;Weiping Xu,&nbsp;Yang Yu,&nbsp;Shasha Bai,&nbsp;Zhilian Chen","doi":"10.1155/2024/3475485","DOIUrl":null,"url":null,"abstract":"<div>\n <p><i>Context</i>. Sanziguben polysaccharides (SZP) have renal protection properties and can reduce renal fibrosis in diabetic nephropathy (DM). However, the mechanism of SZP’s renal protection effect is not yet clear. <i>Objectives</i>. Our study intended to clarify the mechanism of SZP’s renal protection effect in DM. <i>Materials and Methods</i>. In this study, streptozotocin-induced C57BL/6J diabetic nephropathy mice and high glucose combined with TGF-<i>β</i>1-induced EMT in HK-2 cells were used to investigate the effect of Sanziguben polysaccharides. ShRNA-constructed Nrf2 knockdown HK-2 cells were used to explore the role of Nrf2 in Sanziguben polysaccharides inhibiting epithelial-mesenchymal transition. <i>Results</i>. In vivo, the results showed that Sanziguben polysaccharides improved renal epithelial-mesenchymal transition and oxidative stress, and SZP was shown to activate the renal Nrf2, increase Smad7, and inhibit the expression of TGF-<i>β</i>1 (1.05- to 0.71-fold, 1.66- to 0.40-fold and 0.96- to 1.31-fold, respectively). In vitro, SZP ameliorated HK-2 cell epithelial-mesenchymal transition induced by HG combined with TGF-<i>β</i>1, increased the expression of Nrf2 and Smad7, and suppressed the expression of TGF-<i>β</i>1 (1.50- to 1.12-fold, 1.49- to 1.07-fold, and 0.94- to 1.38-fold, respectively). In addition, the above effects of Sanziguben polysaccharides on Nrf2 knockdown HK-2 cells were weakened. <i>Conclusions</i>. The findings suggest that Sanziguben polysaccharides may improve renal epithelial-mesenchymal transition in diabetic nephropathy through Nrf2-mediated regulation of TGF-<i>β</i>1/Smad7 signaling pathway.</p>\n </div>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2024 1","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2024-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/3475485","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Pharmacy and Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/2024/3475485","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Context. Sanziguben polysaccharides (SZP) have renal protection properties and can reduce renal fibrosis in diabetic nephropathy (DM). However, the mechanism of SZP’s renal protection effect is not yet clear. Objectives. Our study intended to clarify the mechanism of SZP’s renal protection effect in DM. Materials and Methods. In this study, streptozotocin-induced C57BL/6J diabetic nephropathy mice and high glucose combined with TGF-β1-induced EMT in HK-2 cells were used to investigate the effect of Sanziguben polysaccharides. ShRNA-constructed Nrf2 knockdown HK-2 cells were used to explore the role of Nrf2 in Sanziguben polysaccharides inhibiting epithelial-mesenchymal transition. Results. In vivo, the results showed that Sanziguben polysaccharides improved renal epithelial-mesenchymal transition and oxidative stress, and SZP was shown to activate the renal Nrf2, increase Smad7, and inhibit the expression of TGF-β1 (1.05- to 0.71-fold, 1.66- to 0.40-fold and 0.96- to 1.31-fold, respectively). In vitro, SZP ameliorated HK-2 cell epithelial-mesenchymal transition induced by HG combined with TGF-β1, increased the expression of Nrf2 and Smad7, and suppressed the expression of TGF-β1 (1.50- to 1.12-fold, 1.49- to 1.07-fold, and 0.94- to 1.38-fold, respectively). In addition, the above effects of Sanziguben polysaccharides on Nrf2 knockdown HK-2 cells were weakened. Conclusions. The findings suggest that Sanziguben polysaccharides may improve renal epithelial-mesenchymal transition in diabetic nephropathy through Nrf2-mediated regulation of TGF-β1/Smad7 signaling pathway.

Abstract Image

桑孜古本多糖通过 Nrf2 介导的 TGF-β1/Smad7 信号通路调控,减缓糖尿病肾病中的肾上皮-间质转化
背景。桑日古本多糖(SZP)具有保护肾脏的特性,可以减轻糖尿病肾病(DM)患者的肾脏纤维化。然而,SZP 保护肾脏作用的机制尚不清楚。研究目的我们的研究旨在阐明 SZP 对 DM 肾脏保护作用的机制。材料与方法。本研究以链脲佐菌素诱导的 C57BL/6J 糖尿病肾病小鼠和高糖联合 TGF-β1 诱导的 HK-2 细胞 EMT 为研究对象。用 ShRNA 构建的 Nrf2 敲除 HK-2 细胞来探讨 Nrf2 在桑梓古本多糖抑制上皮-间质转化中的作用。结果显示结果表明,在体内,桑梓古本多糖可改善肾脏上皮-间质转化和氧化应激,SZP可激活肾脏Nrf2、增加Smad7和抑制TGF-β1的表达(分别为1.05-0.71倍、1.66-0.40倍和0.96-1.31倍)。在体外,SZP 可改善 HG 联合 TGF-β1 诱导的 HK-2 细胞上皮-间质转化,增加 Nrf2 和 Smad7 的表达,抑制 TGF-β1 的表达(分别为 1.50-1.12 倍、1.49-1.07 倍和 0.94-1.38 倍)。此外,桑孜古本多糖对 Nrf2 敲除的 HK-2 细胞的上述作用也有所减弱。结论研究结果表明,桑枝多糖可通过 Nrf2 介导的 TGF-β1/Smad7 信号通路调控改善糖尿病肾病的肾上皮-间充质转化。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.10
自引率
5.00%
发文量
226
审稿时长
6 months
期刊介绍: The Journal of Clinical Pharmacy and Therapeutics provides a forum for clinicians, pharmacists and pharmacologists to explore and report on issues of common interest. Reports and commentaries on current issues in medical and pharmaceutical practice are encouraged. Papers on evidence-based clinical practice and multidisciplinary collaborative work are particularly welcome. Regular sections in the journal include: editorials, commentaries, reviews (including systematic overviews and meta-analyses), original research and reports, and book reviews. Its scope embraces all aspects of clinical drug development and therapeutics, including: Rational therapeutics Evidence-based practice Safety, cost-effectiveness and clinical efficacy of drugs Drug interactions Clinical impact of drug formulations Pharmacogenetics Personalised, stratified and translational medicine Clinical pharmacokinetics.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信